Oct 2026· Frontiers in Cardiovascular Medicine· Vol 13· 0 citations· 35 references
TL;DR
The randomized trial-level evidence evaluated here is insufficient to validate short-term weight change as a surrogate for post-discharge clinical outcomes in AHF and showed a directional but non-robust trial-level association with clinical benefit.
Abstract
Body weight, urine output, urinary sodium, and ultrasound findings are frequently used as early trial endpoints in acute heart failure (AHF). However, patient-level prognostic associations with residual congestion do not establish the fact that treatment-induced marker improvement predicts fewer deaths or heart failure events.
The objectives of this work are to pair short-term decongestion and subsequent clinical treatment effects within the same randomized comparisons, explore the trial-level association for body weight, and qualitatively assess non-weight markers.
PubMed/MEDLINE, OpenAlex, and ClinicalTrials.gov databases were searched through 18 July 2026. Eligible randomized adult AHF trials reported an objective decongestion effect and ≥30-day mortality, heart failure events, or rehospitalization. The amended primary marker was weight change at 24–96 h (original window, 48–96 h); clinical effects were log hazard or risk ratios. An errors-in-variables meta-regression model used 10,000 trial cluster bootstrap fits and trial-level jackknife intervals.
Twenty-four trials (27 reports) were accepted for qualitative synthesis; the primary analysis included 12 comparisons from only 10 independent trials. Endpoints, follow-up (30–302 days), effect measures, and mechanisms were heterogeneous. Each additional 1-kg between-group difference in weight loss corresponded to a clinical effect ratio of 0.74 (percentile 95% interval, 0.56–1.26; jackknife, 0.49–1.11). The pharmacological-only estimate was 1.04. Evidence for urine output, urinary sodium, and ultrasound was also inconsistent.
Short-term weight loss showed a directional but non-robust trial-level association with clinical benefit. The randomized trial-level evidence evaluated here is insufficient to validate short-term weight change as a surrogate for post-discharge clinical outcomes in AHF.
The observed dose-response relationship supports consideration of D2D time as a potential systems-level quality metric, warranting prospective validation, and suggests amplification of the survival gradient in registries with higher baseline mortality rates.
M. Ghozali, N. D. Putri· European Heart Journal, Supp...· 0 citations
Approximately 50% of heart failure (HF) patients are malnourished, doubling mortality risk; however, interventional evidence remains limited. A previously published meta-analysis found modest weight improvements only in malnourished/cachectic patients (5 studies, n = 275). This review updates the evidence in a broader...
Muazma Batool, N. Duseja, M. Mustafa et al.· Cardiology in Review· 0 citations
Early adjunctive therapies may improve decongestion and symptoms in acute heart failure. This trial compared dapagliflozin with acetazolamide when initiated early, focusing on dyspnea relief as the primary outcome and decongestive, diuretic, natriuretic, and safety outcomes. In this randomized, active-controlled trial,...
Hossam Sharaf, M. Wadie, N. O. Mansour et al.· Clinical pharmacology and th...· 0 citations
Replacing regular salt with potassium-enriched formulations (75/25) is an efficacious strategy for BP reduction and MACE prevention and future studies should focus on Western populations to address dietary heterogeneity and consolidate generalisability.
G. Â. Alves, T. Bonafé, B. Souza et al.· European Heart Journal· 0 citations
Inflammation and malnutrition are important contributors to adverse outcomes in heart failure (HF). The neutrophil percentage-to-albumin ratio (NPAR), derived from routinely available laboratory parameters, integrates inflammatory burden and nutritional status and may provide prognostic value. We conducted a systematic...
P. Adrejiya, Aditi K. Bhanushali, P. Suchday et al.· Cardiology in Review· 0 citations
In this exploratory real-world cohort of patients with advanced HF and refractory congestion, both outpatient furosemide strategies were associated with short-term decongestion, with differences observed in symptomatic response.
R. López-Vilella, Borja Guerrero Cervera, Emilio Monte Boquet et al.· Biomedicines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.